NCT00203606View on ClinicalTrials.gov

Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

August 31, 2011

Conditions
Hepatitis c
Interventions
DRUG

pegylated interferon alfa-2a ( Roche) and ribavirin

pegylated interferon alfa-2a ( Roche) and ribavirin

Trial Locations (2)

T2N4N1

University of Calgary, Calgary

Unknown

Pender Clinic, Vancouver

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Roche Pharma AG

INDUSTRY

lead

University of Calgary

OTHER

NCT00203606 - Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C | Biotech Hunter | Biotech Hunter